Literature DB >> 18563459

Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-girdle muscular dystrophy 2A diagnosis.

L Blázquez1, M Azpitarte, A Sáenz, M Goicoechea, D Otaegui, X Ferrer, I Illa, E Gutierrez-Rivas, J J Vilchez, A López de Munain.   

Abstract

Limb-girdle muscular dystrophy type 2A (LGMD2A) is an autosomal recessive disorder caused by mutations in the CAPN3 gene. Its definitive diagnosis is laborious, since the clinical phenotype is often similar to other types of muscular dystrophy and since the CAPN3 gene encompasses a large genomic region with more than 300 pathogenic mutations described to date. In fact, it is estimated that nearly 25% of the cases with a phenotype suggestive of LGMD2A do not have mutations in the CAPN3 gene and that, in up to 22% of the cases, only one mutation is identified. In the present work, we have characterised CAPN3 messenger RNA (mRNA) expression in peripheral blood, and we have performed a retrospective diagnostic study with 26 LGMD2A patients, sequencing a transcript of CAPN3 present in white blood cells (WBCs). The 25% of the mutations presented in this paper (7/28) act modifying pre-mRNA splicing of the CAPN3 transcript, including the first deep-intronic mutation described to date in the CAPN3 gene. Our results determine that the sequencing of CAPN3 transcripts present in WBCs could be applied as a new approach for LGMD2A diagnosis. This method improves and simplifies diagnosis, since it combines the advantages of mRNA analysis in a more accessible and rapidly regenerated tissue. However, the lack of exon 15 in the CAPN3 isoforms present in blood, and the presence of mRNA degradation make it necessary to combine mRNA and DNA analyses in some specific cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18563459     DOI: 10.1007/s10048-008-0129-1

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Influence of specific regions in Lp82 calpain on protein stability, activity, and localization within lens.

Authors:  H Ma; M Shih; C Fukiage; M Azuma; M K Duncan; N A Reed; I Richard; J S Beckmann; T R Shearer
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

3.  Insertion sequence 1 of muscle-specific calpain, p94, acts as an internal propeptide.

Authors:  Beatriz Garcia Diaz; Tudor Moldoveanu; Michael J Kuiper; Robert L Campbell; Peter L Davies
Journal:  J Biol Chem       Date:  2004-04-08       Impact factor: 5.157

Review 4.  PCR-SSCP: a method for detection of mutations.

Authors:  K Hayashi
Journal:  Genet Anal Tech Appl       Date:  1992-06

5.  Quantitative analysis of CAPN3 transcripts in LGMD2A patients: involvement of nonsense-mediated mRNA decay.

Authors:  Kristýna Stehlíková; Eva Zapletalová; Jana Sedlácková; Markéta Hermanová; Petr Vondrácek; Tat'ána Maríková; Radim Mazanec; Josef Zámecník; Stanislav Vohánka; Jirí Fajkus; Lenka Fajkusová
Journal:  Neuromuscul Disord       Date:  2006-12-08       Impact factor: 4.296

6.  Lp85 calpain is an enzymatically active rodent-specific isozyme of lens Lp82.

Authors:  H Ma; M Shih; I Hata; C Fukiage; M Azuma; T R Shearer
Journal:  Curr Eye Res       Date:  2000-03       Impact factor: 2.424

7.  A deep intronic mutation in the RB1 gene leads to intronic sequence exonisation.

Authors:  Catherine Dehainault; Dorothée Michaux; Sabine Pagès-Berhouet; Virginie Caux-Moncoutier; François Doz; Laurence Desjardins; Jérôme Couturier; Philippe Parent; Dominique Stoppa-Lyonnet; Marion Gauthier-Villars; Claude Houdayer
Journal:  Eur J Hum Genet       Date:  2007-02-14       Impact factor: 4.246

8.  Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.

Authors:  Liat Linde; Stephanie Boelz; Malka Nissim-Rafinia; Yifat S Oren; Michael Wilschanski; Yasmin Yaacov; Dov Virgilis; Gabriele Neu-Yilik; Andreas E Kulozik; Eitan Kerem; Batsheva Kerem
Journal:  J Clin Invest       Date:  2007-02-08       Impact factor: 14.808

9.  Dysferlin expression in monocytes: a source of mRNA for mutation analysis.

Authors:  N De Luna; A Freixas; P Gallano; L Caselles; R Rojas-García; C Paradas; G Nogales; R Dominguez-Perles; L Gonzalez-Quereda; J J Vílchez; C Márquez; J Bautista; A Guerrero; J A Salazar; A Pou; I Illa; E Gallardo
Journal:  Neuromuscul Disord       Date:  2006-10-27       Impact factor: 4.296

10.  Characterization of a new p94-like calpain form in human lymphocytes.

Authors:  Roberta De Tullio; Roberto Stifanese; Franca Salamino; Sandro Pontremoli; Edon Melloni
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

View more
  12 in total

1.  Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity.

Authors:  Sabrina Sacconi; Pilar Camaño; Jessica C de Greef; Richard J L F Lemmers; Leonardo Salviati; Pascal Boileau; Adolfo Lopez de Munain Arregui; Silvère M van der Maarel; Claude Desnuelle
Journal:  J Med Genet       Date:  2011-10-07       Impact factor: 6.318

2.  Clinical and Genomic Evaluation of 207 Genetic Myopathies in the Indian Subcontinent.

Authors:  Samya Chakravorty; Babi Ramesh Reddy Nallamilli; Satish Vasant Khadilkar; Madhu Bala Singla; Ashish Bhutada; Rashna Dastur; Pradnya Satish Gaitonde; Laura E Rufibach; Logan Gloster; Madhuri Hegde
Journal:  Front Neurol       Date:  2020-11-05       Impact factor: 4.086

3.  Calpain3 is expressed in a proteolitically active form in papillomavirus-associated urothelial tumors of the urinary bladder in cattle.

Authors:  Sante Roperto; Roberta De Tullio; Cinzia Raso; Roberto Stifanese; Valeria Russo; Marco Gaspari; Giuseppe Borzacchiello; Monica Averna; Orlando Paciello; Gianni Cuda; Franco Roperto
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

4.  Identification of a Novel Deep Intronic Mutation in CAPN3 Presenting a Promising Target for Therapeutic Splice Modulation.

Authors:  Ying Hu; Payam Mohassel; Sandra Donkervoort; Pomi Yun; Véronique Bolduc; Daniel Ezzo; Jahannaz Dastgir; Jamie L Marshall; Monkol Lek; Daniel G MacArthur; A Reghan Foley; Carsten G Bönnemann
Journal:  J Neuromuscul Dis       Date:  2019

5.  Transcriptional and translational effects of intronic CAPN3 gene mutations.

Authors:  Anna Chiara Nascimbeni; Marina Fanin; Elisabetta Tasca; Corrado Angelini
Journal:  Hum Mutat       Date:  2010-09       Impact factor: 4.878

6.  NOVEL intronic CAPN3 Roma mutation alters splicing causing RNA mediated decay.

Authors:  Fabiola Mavillard; Marcos Madruga-Garrido; Eloy Rivas; Emilia Servián-Morilla; Rainiero Ávila-Polo; Irene Marcos; Francisco J Morón; Carmen Paradas; Macarena Cabrera-Serrano
Journal:  Ann Clin Transl Neurol       Date:  2019-10-14       Impact factor: 4.511

7.  Mutational spectrum of autosomal recessive limb-girdle muscular dystrophies in a cohort of 112 Iranian patients and reporting of a possible founder effect.

Authors:  Marzieh Mojbafan; Reza Bahmani; Samira Dabbagh Bagheri; Zohreh Sharifi; Sirous Zeinali
Journal:  Orphanet J Rare Dis       Date:  2020-01-14       Impact factor: 4.123

Review 8.  Limb-girdle muscular dystrophies: where next after six decades from the first proposal (Review).

Authors:  Omar A Mahmood; Xin Mei Jiang
Journal:  Mol Med Rep       Date:  2014-03-13       Impact factor: 2.952

9.  A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides.

Authors:  Janice A Dominov; Ozgün Uyan; Peter C Sapp; Diane McKenna-Yasek; Babi R R Nallamilli; Madhuri Hegde; Robert H Brown
Journal:  Ann Clin Transl Neurol       Date:  2014-09-27       Impact factor: 4.511

Review 10.  Calcium Mechanisms in Limb-Girdle Muscular Dystrophy with CAPN3 Mutations.

Authors:  Jaione Lasa-Elgarresta; Laura Mosqueira-Martín; Neia Naldaiz-Gastesi; Amets Sáenz; Adolfo López de Munain; Ainara Vallejo-Illarramendi
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.